- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Virax Biolabs Collaborating With Emory University On Clinical Studies | 1 | pulse2.com | ||
| 27.08. | Virax Biolabs (VRAX) Falls 18% on Lack of Leads | 1 | Insider Monkey | ||
| 26.08. | Virax Biolabs partners with Emory for long COVID diagnostic studies | 1 | Investing.com | ||
| 26.08. | Virax Biolabs startet mit Emory University Studien zur Long-COVID-Diagnostik | 1 | Investing.com Deutsch | ||
| 26.08. | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 99 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 26.08. | EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies | 2 | Benzinga.com | ||
| 30.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.07. | Virax Biolabs appoints Iain Miller as independent director | 1 | Investing.com | ||
| 18.07. | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| 18.07. | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 5 | Seeking Alpha | ||
| 18.07. | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 144 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
| 02.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 13.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 31.03. | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 163 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
| 13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
| 13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 554 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,05 | +0,05 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | Evotec-Aktie: Ist das ein wichtiges Signal? | Die Evotec-Aktie bewegt sich weiterhin auf einem sehr niedrigen Niveau; am Montag verbessert sie sich aktuell um +1,5% und steht bei rund 6,10 €. Was bei dem deutschen Biotech-Unternehmen fehlt, sind... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,150 | -3,68 % | Ginkgo Bioworks enters into $100M equity sales deal | ||
| GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Issues Stockholder Letter and Provides 2025 Corporate Update | Company Achieves Multiple Clinical Development Milestones in 2025
Patient Treatment Continues in Two Lung Cancer Clinical Trials
AUSTIN, Texas, Aug. 4, 2025 ... ► Artikel lesen | |
| PALISADE BIO | 0,630 | +1,58 % | Palisade Bio, Inc.: Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) | First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated... ► Artikel lesen | |
| GRITSTONE BIO | 0,016 | -100,00 % | Gritstone bio, Inc. - 15-12G, Securities registration termination | ||
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Strategische Impfstoff-Entwicklungen und Finanzierungspläne vorgestellt | ||
| ANNOVIS BIO | 1,922 | -2,34 % | Annovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,000 | -1,64 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial... ► Artikel lesen | |
| HUMACYTE | 1,435 | -1,71 % | Humacyte, Inc: Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update | - Commenced market launch and first commercial sales of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,029 (-4,91 %) liegt der Kurs bei 0,566 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.